Excipient-Control Strategies - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Excipient-Control Strategies
The authors outline excipient-control strategies and practices for the manufacture, distribution, and receipt of excipients.


Pharmaceutical Technology


Looking forward

By following the measures described in this article, the excipient supply chain can continue to provide excipients that are suitable for use in pharmaceuticals.

Irwin Silverstein*, PhD, is vice-president and chief operating officer, and Arthur Falk, PhD, is president and CEO, both at International Pharmaceutical Excipients Auditing,1655 N. Fort Myer Drive, Suite 700, Arlington, VA 22209, tel. 703.351.5266,
. Dale Carter, MS, is global director of quality of J.M. Huber's silica business unit. Maria Guazzaroni Jacobs, PhD, is director of quality and regulatory policy for worldwide pharmaceutical sciences at Pfizer. David Schoneker is director of global regulatory affairs at Colorcon, chairman of the International Pharmaceutical Excipients Council of the Americas (IPEC–Americas), and a member of Pharmaceutical Technology's Editorial Advisory Board.

*To whom all correspondence should be addressed.

References

1. Code of Federal Regulations, Title 21 Food and Drugs (US Government Printing Office, Washington, DC) Part 110, pp. 216–226.

2. IPEC, "White Paper on Excipient Pedigree," manuscript in progress as of Sept. 3, 2008.

3. IPEC–Americas, Standardized Excipient Information Protocol User Guide (Arlington, VA, 2005).

4. D. Klug, A. Van Meter, and Laura Horne, "The Excipient Information Package, A Win–Win Solution," Pharm. Technol. 31 (11), 121–122 (2007).

5. USP 31–NF 26 General Chapter <1078>, "Good Manufacturing Practices for Excipients."

6. IPEC, The Joint IPEC–PQG Good Manufacturing Practices Guide for Bulk Excipients (2006).

7. IPEC, The Joint IPEC–PQG Good Manufacturing Practices Audit Guide for Pharmaceutical Excipients (2007).

8. IPEC, The IPEC Good Distribution Practices Guide for Pharmaceutical Excipients (2006).

9. IPEC, The IPEC Good Distribution Practices Guide for Pharmaceutical Excipients (2008).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here